Guardant Health (NASDAQ:GH) Price Target Raised to $135.00 at JPMorgan Chase & Co.

Guardant Health (NASDAQ:GH) had its price target hoisted by JPMorgan Chase & Co. from $130.00 to $135.00 in a research report released on Friday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

GH has been the topic of several other reports. Piper Sandler boosted their target price on shares of Guardant Health from $120.00 to $130.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 24th. UBS Group restated a “buy” rating and set a $175.00 target price on shares of Guardant Health in a research report on Friday, January 30th. Mizuho set a $135.00 target price on shares of Guardant Health in a research report on Friday, January 9th. TD Cowen boosted their target price on shares of Guardant Health from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Finally, Robert W. Baird initiated coverage on shares of Guardant Health in a research report on Tuesday, February 17th. They set an “outperform” rating and a $120.00 target price on the stock. Nineteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $129.16.

Guardant Health Price Performance

Shares of Guardant Health stock opened at $95.70 on Friday. The firm’s fifty day simple moving average is $88.93 and its 200-day simple moving average is $96.92. The stock has a market capitalization of $12.69 billion, a price-to-earnings ratio of -28.23 and a beta of 1.48. Guardant Health has a 12 month low of $36.36 and a 12 month high of $120.74.

Guardant Health (NASDAQ:GH) last announced its earnings results on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The firm had revenue of $281.27 million for the quarter, compared to analyst estimates of $269.74 million. During the same quarter last year, the firm earned ($0.62) earnings per share. Guardant Health’s revenue for the quarter was up 39.4% on a year-over-year basis. Analysts anticipate that Guardant Health will post -2.87 earnings per share for the current year.

Insider Activity

In related news, Director Medina Manuel Hidalgo sold 1,300 shares of the business’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $91.54, for a total value of $119,002.00. Following the completion of the transaction, the director owned 1,193 shares of the company’s stock, valued at approximately $109,207.22. The trade was a 52.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Terilyn J. Monroe sold 3,832 shares of the company’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $92.68, for a total transaction of $355,149.76. Following the transaction, the insider directly owned 20,990 shares of the company’s stock, valued at approximately $1,945,353.20. This represents a 15.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 8,596 shares of company stock worth $775,767. Company insiders own 6.10% of the company’s stock.

Institutional Trading of Guardant Health

A number of institutional investors and hedge funds have recently bought and sold shares of GH. V Square Quantitative Management LLC acquired a new stake in Guardant Health during the 4th quarter worth approximately $27,000. Chesapeake Asset Management LLC purchased a new position in Guardant Health in the 4th quarter worth approximately $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in Guardant Health in the 4th quarter worth approximately $31,000. Elyxium Wealth LLC purchased a new position in Guardant Health in the 4th quarter worth approximately $35,000. Finally, Parallel Advisors LLC boosted its holdings in Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after acquiring an additional 219 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health News Roundup

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Guardant Health reported Q1 2026 revenue of $301.7 million, well above Wall Street expectations, with revenue up 48% year over year and oncology test volume rising sharply. Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
• Positive Sentiment: The company beat earnings estimates with a smaller-than-expected quarterly loss of $0.45 per share, signaling improving operating performance. Guardant Health (GH) Reports Q1 Loss, Beats Revenue Estimates
• Positive Sentiment: Guardant Health raised its 2026 revenue guidance, reinforcing confidence in continued demand and execution. Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
• Positive Sentiment: JPMorgan Chase & Co. raised its price target on GH to $135 from $130 and reiterated an overweight rating, implying further upside from current levels. Benzinga report on JPMorgan price target increase
• Neutral Sentiment: Investors are also digesting the company’s earnings call transcript and presentation for more detail on management’s outlook and product momentum. Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transcript

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.